Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder
19 juil. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
Intravail® Increased the Rate of Absorption of Intranasal Naltrexone No Serious Adverse Events or Evidence of Nasal Irritation Contract Signed with Renaissance to Advance Product Development SANTA...
Opiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug Delivery Technology
28 juin 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
27 juin 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
Opiant Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update
15 juin 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxone Nasal Spray
27 mars 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
20 mars 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update
16 mars 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray Patents
09 mars 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder
28 févr. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
Opiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer
06 févr. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...